Trial Profile
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Registrational; Therapeutic Use
- 27 Jan 2024 Results (n=89) assessing the capacity of the urinary comprehensive genomic profile (uCGP) to predict event-free survival (EFS) in patients with BU-NMIBC treated with atezolizumab presented at the 2024 Genitourinary Cancers Symposium
- 01 Dec 2023 Primary endpoint has not been met. (Complete response (CR) rate in the subset of patients with carcinoma in situ (CIS) based on biopsy) , according to Results published in the European Urology
- 01 Dec 2023 Results published in the European Urology